Biotechnology News and Research

RSS

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

Maize-derived collagen has proline hydroxylation levels similar to human collagen

Synthetic collagen has a wide range of applications in reconstructive and cosmetic surgery and in the food industry. For proper function in animals a certain number of prolines within the protein need to be hydroxylated. BioMed Central's open access journal BMC Biotechnology reports that for the first time the α1 chain of type 1 collagen has been produced in maize with similar levels of proline hydroxylation to human collagen.

24 Jun 2011

ABA honors Acorda Therapeutics president with 2011 Stevie Award

Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., President and CEO of Acorda Therapeutics, was awarded the 2011 Stevie Award for Executive of the Year in the Health Products & Services category at the 9th Annual American Business Awards (ABA) ceremony held on June 20, 2011.

24 Jun 2011

GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a third site for testing the therapeutic potential of its HIV/AIDS vaccine.

24 Jun 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.

24 Jun 2011

Scil Technology receives public research grant for novel rheumatoid arthritis treatments

Scil Technology GmbH, a biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced that it has been awarded research funding by the German Federal Ministry of Education and Research (BMBF) under BMBF’s KMU-innovativ scheme. The EUR 0.9 million grant supports Scil Technology’s research program to explore the therapeutic potential of repellent proteins for the treatment of rheumatoid arthritis (RA).

23 Jun 2011

New proteomics-based approach to analyze bone quality

A new technique developed at Rensselaer Polytechnic Institute allows researchers to collect large amounts of biochemical information from nanoscale bone samples.

23 Jun 2011

FDA grants Fast Track designation for Repligen's RG3039 to treat Spinal Muscular Atrophy

Repligen Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RG3039, a potential treatment for Spinal Muscular Atrophy.

23 Jun 2011

Insight into future development of global pharmaceutical industry

Alacrita, which is changing the face of life science consulting, has published an insight into the future development of the global pharmaceutical industry.

23 Jun 2011

Axxam receives ADDF grant to develop new therapeutics for Alzheimer's

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant to Axxam SpA to develop small molecules to treat Alzheimer's disease by targeting inflammation.

23 Jun 2011

Mothers receiving influenza vaccination during pregnancy also protect infants

Infants born to mothers who received the influenza (flu) vaccine while pregnant are nearly 50 percent less likely to be hospitalized for the flu than infants born to mothers who did not receive the vaccine while pregnant, according to a new collaborative study by researchers at Wake Forest Baptist Medical Center and colleagues.

23 Jun 2011

BioCision releases three new cryopreservation systems

BioCision, the coolprep company, today announced the release of three new cryopreservation systems: CoolCell FTS30, the first large-capacity, high-density cell freezing system; CoolCell SV2 for freezing cells in larger diameter 2ml vials; and CoolCell 5ml for large cryovial freezing.

22 Jun 2011

VENENUM opens new medicinal chemistry facility in Hamilton, NJ

VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify potential therapeutic agents against its novel disease-based targets, or its partners' targets, announced today that it opened its new medicinal chemistry space at 8 Black Forest Road in Hamilton, NJ.

22 Jun 2011

22nd Century submits IND to FDA for VLN cigarettes

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction, announced today that 22nd Century Limited, LLC submitted an Investigational New Drug Application (IND) to the U.S. Food & Drug Administration (FDA) for X-22, a prescription smoking cessation aid in development.

22 Jun 2011

Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis

Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis.

22 Jun 2011

Human retina protein can sense Earth's magnetic field

For migratory birds and sea turtles, the ability to sense the Earth's magnetic field is crucial to navigating the long-distance voyages these animals undertake during migration. Humans, however, are widely assumed not to have an innate magnetic sense.

22 Jun 2011

ImmunoCellular Therapeutics receives U.S. patent for cancer vaccine technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a U.S. patent relating to a technology for the treatment of cancer for which the Company holds an exclusive, worldwide license.

22 Jun 2011

Celerion generates over 25,000 platelet aggregation samples, achieves major milestone

Celerion, the premier provider of innovative early stage drug development solutions, announces it has achieved a major milestone of generating over 25,000 platelet aggregation sample results.

22 Jun 2011

AusBiotech supports ‘Raising the Bar’

AusBiotech welcomes a legislative Bill that has been introduced into the Australian Parliament today - The Intellectual Property Laws Amendment (Raising the Bar) Bill 2011.

21 Jun 2011

Indian biotechnology market to reach over $11 billion by 2017

The Indian biotechnology market is set to reach over $11 billion by 2017, according to a new report available on companiesandmarkets.com. The market will be driven by foreign investment, growing R&D and infrastructure investment, an emerging contract research market, drug discovery and growth in manufacturing outsourcing to India.

21 Jun 2011